DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/pq3frt/acute_ischemic) has announced the addition of Decision Resources, Inc's new report "Acute Ischemic Stroke (Event Driven)" to their offering.
Acute ischemic stroke (AIS) is one of the leading causes of death and neurological disability worldwide: in 2010, we estimate, 1.8 million ischemic strokes occurred in the seven major pharmaceutical markets. Fifteen years after its approval, recombinant tissue plasminogen activator (rt-PA; alteplase [Genentech's Activase, other brands]) remains the only pharmacological therapy approved for the acute treatment of ischemic stroke in all markets under study.
However, because of strict inclusion criteria and safety concerns, the drug is administered to fewer than 5% of diagnosed patients. Given the staggering societal costs of stroke and the historical propensity for investigational drugs to fail in the pipeline, there remains a dire need and enormous opportunity for alternative treatmentsbe they thrombolytic, neuroprotective, or neurorestorative drugs or devicesthat can safely and more effectively treat a greater proportion of AIS patients.
Key Topics Covered:
Executive Summary
What are the key parameters of the acute ischemic stroke market?
What factors are driving the market for acute ischemic stroke therapies?
What factors are constraining the market for acute ischemic stroke therapies?
What are the drug development activities of note in acute ischemic stroke?
Original post:
Research and Markets: Acute Ischemic Stroke (Event Driven) - A Leading Cause of Death and Neurological Disability ...